Your browser doesn't support javascript.
loading
Immune Sensing of Synthetic, Bacterial, and Protozoan RNA by Toll-like Receptor 8 Requires Coordinated Processing by RNase T2 and RNase 2.
Ostendorf, Thomas; Zillinger, Thomas; Andryka, Katarzyna; Schlee-Guimaraes, Thais Marina; Schmitz, Saskia; Marx, Samira; Bayrak, Kübra; Linke, Rebecca; Salgert, Sarah; Wegner, Julia; Grasser, Tatjana; Bauersachs, Sonja; Soltesz, Leon; Hübner, Marc P; Nastaly, Maximilian; Coch, Christoph; Kettwig, Matthias; Roehl, Ingo; Henneke, Marco; Hoerauf, Achim; Barchet, Winfried; Gärtner, Jutta; Schlee, Martin; Hartmann, Gunther; Bartok, Eva.
Afiliação
  • Ostendorf T; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Zillinger T; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Andryka K; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Schlee-Guimaraes TM; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Schmitz S; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Marx S; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Bayrak K; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Linke R; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Salgert S; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Wegner J; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Grasser T; Axolabs GmbH, Fritz-Hornschuch-Strasse 9, 95326 Kulmbach, Germany.
  • Bauersachs S; Axolabs GmbH, Fritz-Hornschuch-Strasse 9, 95326 Kulmbach, Germany.
  • Soltesz L; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Hübner MP; Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany.
  • Nastaly M; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Coch C; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; Miltenyi Biotech, Biomedicine Division, Bergisch Gladbach, Germany.
  • Kettwig M; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Georg August University, Göttingen, Germany.
  • Roehl I; Axolabs GmbH, Fritz-Hornschuch-Strasse 9, 95326 Kulmbach, Germany.
  • Henneke M; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Georg August University, Göttingen, Germany.
  • Hoerauf A; Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Barchet W; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Gärtner J; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Georg August University, Göttingen, Germany.
  • Schlee M; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
  • Hartmann G; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany; German Center for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany.
  • Bartok E; Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany. Electronic address: ebartok@uni-bonn.de.
Immunity ; 52(4): 591-605.e6, 2020 04 14.
Article em En | MEDLINE | ID: mdl-32294405
ABSTRACT
Human toll-like receptor 8 (TLR8) activation induces a potent T helper-1 (Th1) cell response critical for defense against intracellular pathogens, including protozoa. The receptor harbors two distinct binding sites, uridine and di- and/or trinucleotides, but the RNases upstream of TLR8 remain poorly characterized. We identified two endolysosomal endoribonucleases, RNase T2 and RNase 2, that act synergistically to release uridine from oligoribonucleotides. RNase T2 cleaves preferentially before, and RNase 2 after, uridines. Live bacteria, P. falciparum-infected red blood cells, purified pathogen RNA, and synthetic oligoribonucleotides all required RNase 2 and T2 processing to activate TLR8. Uridine supplementation restored RNA recognition in RNASE2-/- or RNASET2-/- but not RNASE2-/-RNASET2-/- cells. Primary immune cells from RNase T2-hypomorphic patients lacked a response to bacterial RNA but responded robustly to small-molecule TLR8 ligands. Our data identify an essential function of RNase T2 and RNase 2 upstream of TLR8 and provide insight into TLR8 activation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Bacteriano / Monócitos / RNA de Protozoário / Endorribonucleases / Receptor 8 Toll-Like / Neutrófilos Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: RNA Bacteriano / Monócitos / RNA de Protozoário / Endorribonucleases / Receptor 8 Toll-Like / Neutrófilos Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article